Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

6.8K
6.8K
Amyloid Fibrils03:03

Amyloid Fibrils

12.4K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.4K
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

706
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
706
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

593
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
593
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

731
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
731
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative outcomes of intra-aortic balloon pump versus impella in non-myocardial infarction cardiogenic shock: A National Inpatient Sample Database analysis.

JHLT open·2026
Same author

Biventricular impella support in acute antibody-mediated cardiac allograft rejection with severe hemodynamic compromise.

Journal of cardiothoracic surgery·2026
Same author

Social Determinants of Health and Outcomes in Transthyretin Amyloid Cardiomyopathy.

The American journal of cardiology·2026
Same author

Identification of Heart Transplant Rejection Subtypes With Circulating MicroRNAs.

Circulation. Heart failure·2026
Same author

A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.

Future cardiology·2025
Same author

Left Atrial Dysfunction in Patients with Atrial Fibrillation and Heart Failure.

Current cardiology reports·2025

Related Experiment Video

Updated: Mar 8, 2026

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

14.2K

Light-chain cardiac amyloidosis.

Anit K Mankad1, Isata Sesay2, Keyur B Shah2

  • 1Division of Cardiology, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia.

Current Problems in Cancer
|January 25, 2017
PubMed
Summary
This summary is machine-generated.

Cardiac amyloidosis is often diagnosed late, impacting treatment and outcomes. Differentiating transthyretin amyloidosis from light-chain amyloidosis is crucial for effective management and improved survival.

Keywords:
Cardiac amyloidosisautologousbortezomibheart transplantationlight chain amyloidosisstem cell transplantation

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.7K
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

8.1K

Related Experiment Videos

Last Updated: Mar 8, 2026

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

14.2K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.7K
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

8.1K

Area of Science:

  • Cardiology
  • Cardiovascular Pathology
  • Medical Diagnostics

Background:

  • Cardiac amyloidosis is an underrecognized condition with significant diagnostic delays.
  • Amyloid infiltration leads to diverse cardiac manifestations, from diastolic dysfunction to heart failure.
  • Timely diagnosis is critical for appropriate management and prognosis.

Purpose of the Study:

  • To review the key features of cardiac amyloidosis.
  • To emphasize the importance of differentiating amyloidosis subtypes (transthyretin vs. light-chain).
  • To guide practitioners in managing this complex condition.

Main Methods:

  • Review of existing literature on cardiac amyloidosis.
  • Discussion of diagnostic challenges and clinical presentations.
  • Analysis of current and emerging treatment strategies.

Main Results:

  • Delays in diagnosis negatively affect management options and patient outcomes.
  • Transthyretin amyloidosis and light-chain amyloidosis have distinct clinical courses and treatment considerations.
  • Standard heart failure therapies are often ineffective and may cause adverse effects in cardiac amyloidosis.
  • Bortezomib shows promise as a tolerable treatment for myocardial amyloid infiltration.

Conclusions:

  • Accurate differentiation of amyloidosis subtypes is essential for patient care.
  • Novel therapeutic approaches are needed, as standard treatments offer limited benefit.
  • Early recognition and subtype-specific management can improve outcomes for patients with cardiac amyloidosis.